Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Acadia Pharmaceuticals (Nasdaq: ACAD) has scheduled its fourth quarter and full year 2024 financial results announcement for February 26, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
The webcast will be accessible through Acadia's website investor section until May 26, 2025. Participants can register for the conference call to receive dial-in details and a unique PIN. Acadia is known for developing the first FDA-approved drug for Parkinson's disease psychosis-related hallucinations and delusions, as well as the first approved treatment for Rett syndrome in the United States and Canada. The company's clinical pipeline includes programs for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuro-psychiatric and neuro-rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per 26 febbraio 2025, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 16:30 ora orientale dello stesso giorno.
La trasmissione sarà accessibile attraverso la sezione investitori del sito web di Acadia fino al 26 maggio 2025. I partecipanti possono registrarsi per la conferenza telefonica per ricevere i dettagli di accesso e un PIN unico. Acadia è conosciuta per aver sviluppato il primo farmaco approvato dalla FDA per le allucinazioni e le delusioni correlate alla psicosi della malattia di Parkinson, nonché il primo trattamento approvato per la sindrome di Rett negli Stati Uniti e in Canada. Il pipeline clinico dell'azienda include programmi per la sindrome di Prader-Willi, la psicosi della malattia di Alzheimer e altre malattie neuro-psichiatriche e neuro-rare.
Acadia Pharmaceuticals (Nasdaq: ACAD) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 26 de febrero de 2025, después del cierre del mercado en EE. UU. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 4:30 p.m. hora del Este el mismo día.
La transmisión estará accesible a través de la sección de inversores del sitio web de Acadia hasta el 26 de mayo de 2025. Los participantes pueden registrarse para la llamada de conferencia y recibir detalles de acceso y un PIN único. Acadia es conocida por desarrollar el primer medicamento aprobado por la FDA para las alucinaciones y delirios relacionados con la psicosis de la enfermedad de Parkinson, así como el primer tratamiento aprobado para el síndrome de Rett en Estados Unidos y Canadá. El pipeline clínico de la compañía incluye programas para el síndrome de Prader-Willi, la psicosis de la enfermedad de Alzheimer y otras enfermedades neuropsiquiátricas y neuro-raras.
아카디아 제약 (Nasdaq: ACAD)는 2025년 2월 26일에 2024년 4분기 및 연간 재무 결과 발표를 미국 시장 마감 후로 예정하고 있습니다. 회사는 같은 날 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다.
웹캐스트는 2025년 5월 26일까지 아카디아의 웹사이트 투자자 섹션을 통해 접근할 수 있습니다. 참가자들은 컨퍼런스 콜에 등록하여 전화 접속 정보 및 고유 PIN을 받을 수 있습니다. 아카디아는 파킨슨병의 정신병 관련 환각 및 망상에 대해 FDA 승인을 받은 첫 번째 약물을 개발한 것으로 알려져 있으며, 미국과 캐나다에서 레트 증후군에 대한 첫 번째 승인 치료제를 개발했습니다. 회사의 임상 파이프라인에는 프라더-윌리 증후군, 알츠하이머병 정신병 및 기타 신경정신과 및 신경 희귀 질병에 대한 프로그램이 포함되어 있습니다.
Acadia Pharmaceuticals (Nasdaq: ACAD) a prévu l'annonce de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour le 26 février 2025, après la clôture du marché américain. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 16h30, heure de l'Est.
Le webinaire sera accessible via la section investisseurs du site Web d'Acadia jusqu'au 26 mai 2025. Les participants peuvent s'inscrire à la conférence téléphonique pour recevoir les détails de connexion et un code PIN unique. Acadia est connue pour avoir développé le premier médicament approuvé par la FDA pour les hallucinations et les délires liés à la psychose de la maladie de Parkinson, ainsi que pour le premier traitement approuvé pour le syndrome de Rett aux États-Unis et au Canada. Le pipeline clinique de l'entreprise comprend des programmes pour le syndrome de Prader-Willi, la psychose de la maladie d'Alzheimer et d'autres maladies neuropsychiatriques et neuro-rares.
Acadia Pharmaceuticals (Nasdaq: ACAD) hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 26. Februar 2025 nach Börsenschluss in den USA angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten.
Der Webcast wird bis zum 26. Mai 2025 über den Investorenbereich der Acadia-Website zugänglich sein. Teilnehmer können sich für die Telefonkonferenz registrieren, um Zugangsdaten und eine einzigartige PIN zu erhalten. Acadia ist bekannt dafür, das erste von der FDA zugelassene Medikament gegen Halluzinationen und Wahnvorstellungen im Zusammenhang mit der Psychose der Parkinson-Krankheit entwickelt zu haben, sowie die erste zugelassene Behandlung für das Rett-Syndrom in den Vereinigten Staaten und Kanada. Die klinische Pipeline des Unternehmens umfasst Programme für das Prader-Willi-Syndrom, die Psychose bei Alzheimer und andere neuropsychiatrische sowie neurorare Erkrankungen.
- None.
- None.
Company to host conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. Eastern Time
The webcast will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until May 26, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212601157/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
When will ACAD report its Q4 and full year 2024 earnings?
How can investors access ACAD's Q4 2024 earnings call?
How long will ACAD's Q4 2024 earnings webcast be available?
What are ACAD's main FDA-approved products?
What conditions is ACAD currently developing treatments for?
